The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 03, 2023

Filed:

Nov. 21, 2017
Applicants:

Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;

Université DE Strasbourg, Strasbourg, FR;

Etablissement Français Du Sang (Efs), La Plaine Saint Denis, FR;

Inventors:

Pierre Mangin, Strasbourg, FR;

Christian Gachet, Strasbourg, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61P 35/04 (2006.01); C07K 14/705 (2006.01); C12N 15/115 (2010.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61P 35/04 (2018.01); C07K 14/70503 (2013.01); C12N 15/115 (2013.01); A61K 2039/505 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2319/30 (2013.01); C12N 2310/16 (2013.01); C12N 2320/30 (2013.01);
Abstract

The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of metastases. The inventors showed in vivo that lung metastasis in GPVI deficient mice are reduced compared to controls. They demonstrated that GPVI is involved in platetet interaction with tumor cells and this interaction is mediated by EMMPRIN.). Using an anti-EMMPRIN antibody, they showed that the adhesion of platelets to tumors cells is decreased. In particular, the present invention relates to a method for the prophylactic treatment of metastases in a patient suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent which inhibits the interaction between GPVI and EMMPRIN.


Find Patent Forward Citations

Loading…